Quimioterapia neoadjuvante torna ressecável carcinoma de cabeça de pâncreas
We present a case of non-resectable head pancreatic cancer by mesenteric venous invasion in which treatment with Gemcitabine (Gemzar) 1.000 mg/m 2 weekly for 3 weeks, followed by a 1-week rest, normalized CA 19.9 and promoted tumor resecability in a second operation (ultrasound, helicoidal tomography and magnetic ressonance exams). The value of the adjuvant treatment (radiochemotherapy) and the association with immunotherapy (Interferon) is discussed.
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Digital revista |
| Language: | Portuguese |
| Published: |
Colégio Brasileiro de Cirurgiões
2007
|
| Online Access: | http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0100-69912007000400014 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | We present a case of non-resectable head pancreatic cancer by mesenteric venous invasion in which treatment with Gemcitabine (Gemzar) 1.000 mg/m 2 weekly for 3 weeks, followed by a 1-week rest, normalized CA 19.9 and promoted tumor resecability in a second operation (ultrasound, helicoidal tomography and magnetic ressonance exams). The value of the adjuvant treatment (radiochemotherapy) and the association with immunotherapy (Interferon) is discussed. |
|---|